Evidence map›Paper›PMID 40869053›Full record

ArticleInternational journal of molecular sciences2025

Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota.

Pratibha Malhotra, Ranjith Palanisamy, Arunima Panda, Ilaria Casari, Janina E E Tirnitz-Parker, Fergal O'Gara, Robert Trengove, Krish Ragunath, Jose A Caparros-Martin, Marco Falasca

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pratibha MalhotraCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Ranjith PalanisamyCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Arunima PandaCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.ORCID 0000-0003-1400-980X
Ilaria CasariCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Janina E E Tirnitz-ParkerCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Fergal O'GaraUWA Medical School, The University of Western Australia, Perth, WA 6009, Australia.ORCID 0000-0002-2659-0673
Robert TrengoveCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Krish RagunathCurtin Medical School, Curtin Medical Research Institute, Curtin University, Perth, WA 6845, Australia.
Jose A Caparros-MartinUWA Medical School, The University of Western Australia, Perth, WA 6009, Australia.ORCID 0000-0003-1214-4952
Marco FalascaDepartment of Medicine and Surgery, University of Parma, Via Volturno 39, 43125 Parma, Italy.ORCID 0000-0002-9801-7235

Funding

Zelira Therapeutics NA
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies, with dismal survival rates. Cannabinoids have shown anticancer properties in various cancers, including PDAC. This study aimed to evaluate the anticancer effects of cannabinoids, individually and in combination, and to elucidate their mechanisms of action in a murine PDAC model (KPC mice, KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+) that mimics human disease. Additionally, the study explored the potential link between cannabinoid action, gut microbiota modulation, and bile acid (BA) metabolism. PDAC cell lines and KPC mice were treated with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), either as monotherapy or in combination. Faecal pellets, caecal contents, plasma, and tissues were collected at the survival endpoint for analysis. BA profiling was performed using mass spectrometry, and the faecal microbiota was characterised by sequencing the V3-V4 region of the 16S rRNA gene. While CBD and THC synergistically reduced cell viability in PDAC cell lines, only CBD monotherapy improved survival in KPC mice. Extended survival with CBD was accompanied by changes in gut microbiota composition and BA metabolism, suggesting a possible association. Notably, the effects of CBD were different from those observed with THC alone or in combination with CBD. The study highlights a distinct role for CBD in altering BA profiles, suggesting these changes may predict responses to cannabidiol in PDAC models. Furthermore, the findings propose that targeting BA metabolism could offer a novel therapeutic strategy for PDAC.

Indexed as

Bile Acids and SaltsCannabidiolCarcinoma, Pancreatic DuctalGastrointestinal MicrobiomePancreatic NeoplasmsAnimalsCell Line, TumorCell SurvivalDisease Models, AnimalDronabinolHumansMiceBile Acids and SaltsCannabidiolDronabinolbile acid metabolismbiomarkerscannabidiolcannabinoidsdelta-9-tetrahydrocannabinolgut microbiotapancreatic ductal adenocarcinoma

Identifiers

PMID40869053
PMCPMC12386833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.